GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » Intangible Assets

IBER.U (Ibere Pharmaceuticals) Intangible Assets : $0.00 Mil (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Ibere Pharmaceuticals's intangible assets for the quarter that ended in Sep. 2022 was $0.00 Mil.


Ibere Pharmaceuticals Intangible Assets Historical Data

The historical data trend for Ibere Pharmaceuticals's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals Intangible Assets Chart

Ibere Pharmaceuticals Annual Data
Trend Dec20 Dec21
Intangible Assets
- -

Ibere Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Intangible Assets Get a 7-Day Free Trial - - - - -

Ibere Pharmaceuticals Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Ibere Pharmaceuticals  (NYSE:IBER.U) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Ibere Pharmaceuticals Intangible Assets Related Terms

Thank you for viewing the detailed overview of Ibere Pharmaceuticals's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Ibere Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103
Ibere Pharmaceuticals is a blank check company.
Executives
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes director, 10 percent owner, officer: Chief Operating Officer 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray director, 10 percent owner, officer: Chief Financial Officer 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc 10 percent owner 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines